Summary
0.48 0.05(11.63%)09/18/2024
CohBar Inc (CWBR)
CohBar Inc (CWBR)
Key Facts
1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
11.63 | 11.63 | 12.94 | -4.00 | -36.88 | -83.78 | -98.87 | -65.59 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
Trading Data | ||
Close | 0.48 | |
Open | 0.46 | |
High | 0.49 | |
Low | 0.46 | |
Volume | 5,279 | |
Change | 0.05 | |
Change % | 11.63 | |
Avg Volume (20 Days) | 438 | |
Volume/Avg Volume (20 Days) Ratio | 12.05 | |
52 Week Range | 0.20 - 3.10 | |
Price vs 52 Week High | -84.52% | |
Price vs 52 Week Low | 140.00% | |
Range | 3.33 | |
Gap Up/Down | 0.03 |
Fundamentals | ||
Market Capitalization (Mln) | 1 | |
EBIDTA | -14,262,793 | |
PE Ratio | 0.0000 | |
PEG Ratio | 0.0000 | |
WallStreet Target Price | 4.13 | |
Book Value | 0.2130 | |
Earnings Per Share | -0.2830 | |
EPS Estimate Current Quarter | -0.0800 | |
EPS Estimate Next Quarter | -0.0800 | |
EPS Estimate Current Year | -0.2700 | |
EPS Estimate Next Year | -0.2300 | |
Diluted EPS (TTM) | -0.2830 | |
Revenues | ||
Profit Marging | 0.0000 | |
Operating Marging (TTM) | 0.0000 | |
Return on asset (TTM) | -0.5218 | |
Return on equity (TTM) | -1.0569 | |
Revenue TTM | 0 | |
Revenue per share TTM | 0.0000 | |
Quarterly Revenue Growth (YOY) | 0.0000 | |
Quarterly Earnings Growth (YOY) | 0.0000 | |
Gross Profit (TTM) | 0 |
Dividends | ||
Dividend Share | 0.0000 | |
Dividend Yield | ||
Valuations | ||
Trailing PE | 0.0000 | |
Forward PE | 0.0000 | |
Price Sales (TTM) | 0.0000 | |
Price Book (MRQ) | 2.8483 | |
Revenue Enterprise Value | 0.0000 | |
EBITDA Enterprise Value | 0.0000 | |
Shares | ||
Shares Outstanding | 86,056,304 | |
Shares Float | 67,232,362 | |
Shares Short | 0 | |
Shares Short (Prior Month) | 0 | |
Shares Ratio | 0.00 | |
Short Outstanding (%) | 0.00 | |
Short Float (%) | 0.00 | |
Insider (%) | 15.85 | |
Institutions (%) | 16.27 |
11/27 18:05 EST - businesswire.com
CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K)
MENLO PARK, Calif.--(BUSINESS WIRE)--On November 20, 2023, CohBar, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) of its determination pursuant to Nasdaq Listing Rule 5101 that, based upon the Staff's belief that the Company is a “public shell,” and that the continued listing of the Company's securities is no longer warranted, and the Company's non-compliance with certain board and committee composition listing.
CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K)
MENLO PARK, Calif.--(BUSINESS WIRE)--On November 20, 2023, CohBar, Inc. (the “Company”) was notified by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) of its determination pursuant to Nasdaq Listing Rule 5101 that, based upon the Staff's belief that the Company is a “public shell,” and that the continued listing of the Company's securities is no longer warranted, and the Company's non-compliance with certain board and committee composition listing.
09/19 13:57 EST - businesswire.com
COHBAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of CohBar, Inc. - CWBR
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of CohBar, Inc. (the “Company”) (NasdaqCM: CWBR) with Morphogenesis, Inc. pursuant to which CohBar shareholders will end up owning approximately 15% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
COHBAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of CohBar, Inc. - CWBR
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of CohBar, Inc. (the “Company”) (NasdaqCM: CWBR) with Morphogenesis, Inc. pursuant to which CohBar shareholders will end up owning approximately 15% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
08/14 16:01 EST - globenewswire.com
CohBar Reports Second Quarter 2023 Financial Results
MENLO PARK, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023.
CohBar Reports Second Quarter 2023 Financial Results
MENLO PARK, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023.
05/24 22:56 EST - headlinesoftoday.com
Shareholder Alert: Ademi LLP investigates whether CohBar, Inc. has obtained a Fair Price in its transaction with Morphogenesis, Inc.
MILWAUKEE, May 24, 2023 /PRNewswire/ — Ademi LLP is investigating CohBar (NASDAQ: CWBR) for possible breaches of fiduciary duty and other violations of law in its transaction with Morphogenesis, Inc. Click here to learn how to join the action https://www.ademilaw.com/case/cohbar-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. CohBar public stockholders […]...
Shareholder Alert: Ademi LLP investigates whether CohBar, Inc. has obtained a Fair Price in its transaction with Morphogenesis, Inc.
MILWAUKEE, May 24, 2023 /PRNewswire/ — Ademi LLP is investigating CohBar (NASDAQ: CWBR) for possible breaches of fiduciary duty and other violations of law in its transaction with Morphogenesis, Inc. Click here to learn how to join the action https://www.ademilaw.com/case/cohbar-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you. CohBar public stockholders […]...
05/23 11:44 EST - investorplace.com
Why Is CohBar (CWBR) Stock Up 130% Today?
CohBar (NASDAQ: CWBR ) stock is soaring higher on Tuesday after the company announced a planned merger with Morphogenesis . CohBar and Morphogenesis are planning for an all-stock merger that will see the two combine to create a new company named “TuHURA Biosciences, Inc.” This company will continue to trade its shares on The Nasdaq Capital Market.
Why Is CohBar (CWBR) Stock Up 130% Today?
CohBar (NASDAQ: CWBR ) stock is soaring higher on Tuesday after the company announced a planned merger with Morphogenesis . CohBar and Morphogenesis are planning for an all-stock merger that will see the two combine to create a new company named “TuHURA Biosciences, Inc.” This company will continue to trade its shares on The Nasdaq Capital Market.
05/23 09:34 EST - businesswire.com
CWBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of CohBar, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of CohBar, Inc. (NASDAQ: CWBR) and Morphogenesis, Inc. is fair to CohBar shareholders. Halper Sadeh encourages CohBar shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether CohBar and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for CohBar shareholders; and (2) disclose all material information necessary for CohBar shareholders to adequately assess and value the merger consideration. On behalf of CohBar shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. Halper Sadeh encourages CohBar shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
CWBR Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of CohBar, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of CohBar, Inc. (NASDAQ: CWBR) and Morphogenesis, Inc. is fair to CohBar shareholders. Halper Sadeh encourages CohBar shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether CohBar and its board violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for CohBar shareholders; and (2) disclose all material information necessary for CohBar shareholders to adequately assess and value the merger consideration. On behalf of CohBar shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits. Halper Sadeh encourages CohBar shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
10/26 09:00 EST - globenewswire.com
CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
10/21 13:33 EST - zacks.com
Cohbar Inc. (CWBR) Upgraded to Strong Buy: What Does It Mean for the Stock?
Cohbar Inc. (CWBR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Cohbar Inc. (CWBR) Upgraded to Strong Buy: What Does It Mean for the Stock?
Cohbar Inc. (CWBR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
09/26 18:21 EST - investorplace.com
7 Nasdaq Stocks to Sell Before They Die
As is typical of a bear market, the Nasdaq has led the other major indices lower over the past year. The tech-heavy index is down 28% over the past 12 months compared with a 17% decline in the S&P 500.
7 Nasdaq Stocks to Sell Before They Die
As is typical of a bear market, the Nasdaq has led the other major indices lower over the past year. The tech-heavy index is down 28% over the past 12 months compared with a 17% decline in the S&P 500.
09/23 08:35 EST - pulse2.com
CohBar (CWBR) Stock: 1-For-30 Reverse Split Goes Into Effect
A 1-for-30 reverse split of CohBar (CWBR) stock has gone into effect today. These are the details.
CohBar (CWBR) Stock: 1-For-30 Reverse Split Goes Into Effect
A 1-for-30 reverse split of CohBar (CWBR) stock has gone into effect today. These are the details.
09/06 09:00 EST - globenewswire.com
CohBar to Present at H.C. Wainwright 24th Annual Global Investment Conference
MENLO PARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12 - 14, 2022.
CohBar to Present at H.C. Wainwright 24th Annual Global Investment Conference
MENLO PARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12 - 14, 2022.
08/15 20:11 EST - seekingalpha.com
CohBar, Inc. (CWBR) CEO Joe Sarret on Q2 2022 Results - Earnings Call Transcript
CohBar, Inc. (NASDAQ:CWBR ) Q2 2022 Earnings Conference Call August 15, 2022 5:00 PM ET Company Participants Jordyn Tarazi - Director of IR Joe Sarret - CEO Jeff Biunno - CFO Nick Vlahakis - Acting CMO Kent Grindstaff - SVP, Research Conference Call Participants Kumar Raja - Brookline Capital Markets Operator Good afternoon. My name is Ryan, and I will be your conference operator for today.
CohBar, Inc. (CWBR) CEO Joe Sarret on Q2 2022 Results - Earnings Call Transcript
CohBar, Inc. (NASDAQ:CWBR ) Q2 2022 Earnings Conference Call August 15, 2022 5:00 PM ET Company Participants Jordyn Tarazi - Director of IR Joe Sarret - CEO Jeff Biunno - CFO Nick Vlahakis - Acting CMO Kent Grindstaff - SVP, Research Conference Call Participants Kumar Raja - Brookline Capital Markets Operator Good afternoon. My name is Ryan, and I will be your conference operator for today.
08/01 09:00 EST - globenewswire.com
CohBar to Announce 2022 Second Quarter Financial Results and Provide Business Update on August 15, 2022
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
CohBar to Announce 2022 Second Quarter Financial Results and Provide Business Update on August 15, 2022
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
05/19 16:02 EST - globenewswire.com
CohBar to Present at the H.C. Wainwright Global Investment Conference
MENLO PARK, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today its virtual participation in the 2022 H.C. Wainwright Global Investment Conference.
CohBar to Present at the H.C. Wainwright Global Investment Conference
MENLO PARK, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today its virtual participation in the 2022 H.C. Wainwright Global Investment Conference.
05/16 21:20 EST - seekingalpha.com
CohBar Inc. (CWBR) CEO Joe Sarret on Q1 2022 Results - Earnings Call Transcript
CohBar Inc. (NASDAQ:CWBR ) Q1 2022 Results Conference Call May 16, 2022 5:00 PM ET Company Participants Joe Sarret - CEO Jeff Biunno - CFO Nick Vlahakis - Acting CMO Kent Grindstaff - SVP, Research Conference Call Participants Kristen Kluska - Cantor Fitzgerald Kumar Raja - Brookline Capital Markets Operator Good afternoon. My name is John, and I will be your conference operator today.
CohBar Inc. (CWBR) CEO Joe Sarret on Q1 2022 Results - Earnings Call Transcript
CohBar Inc. (NASDAQ:CWBR ) Q1 2022 Results Conference Call May 16, 2022 5:00 PM ET Company Participants Joe Sarret - CEO Jeff Biunno - CFO Nick Vlahakis - Acting CMO Kent Grindstaff - SVP, Research Conference Call Participants Kristen Kluska - Cantor Fitzgerald Kumar Raja - Brookline Capital Markets Operator Good afternoon. My name is John, and I will be your conference operator today.
05/02 09:00 EST - globenewswire.com
CohBar to Announce 2022 First Quarter Financial Results and Provide Business Update on May 16, 2022
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
CohBar to Announce 2022 First Quarter Financial Results and Provide Business Update on May 16, 2022
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
03/29 22:44 EST - seekingalpha.com
CohBar, Inc. (CWBR) CEO Joe Sarret on Q4 2021 Results - Earnings Call Transcript
CohBar, Inc. (CWBR) CEO Joe Sarret on Q4 2021 Results - Earnings Call Transcript
CohBar, Inc. (CWBR) CEO Joe Sarret on Q4 2021 Results - Earnings Call Transcript
CohBar, Inc. (CWBR) CEO Joe Sarret on Q4 2021 Results - Earnings Call Transcript
03/15 09:00 EST - globenewswire.com
CohBar to Announce 2021 Fourth Quarter and Full-Year Financial Results and Provide Business Update on March 29, 2022
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
CohBar to Announce 2021 Fourth Quarter and Full-Year Financial Results and Provide Business Update on March 29, 2022
Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
01/03 09:00 EST - globenewswire.com
CohBar to Present at H.C. Wainwright BIOCONNECT Conference
MENLO PARK, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright BIOCONNECT Conference, being held virtually January 10 - 14, 2022.
CohBar to Present at H.C. Wainwright BIOCONNECT Conference
MENLO PARK, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright BIOCONNECT Conference, being held virtually January 10 - 14, 2022.
12/31 11:22 EST - investorplace.com
7 of the Best Penny Stocks Under $3 for 2022 to Buy Now
Penny stocks under $3 are full of potential and potential pitfalls. These are relatively safe and worth your consideration.
7 of the Best Penny Stocks Under $3 for 2022 to Buy Now
Penny stocks under $3 are full of potential and potential pitfalls. These are relatively safe and worth your consideration.